simvastatin has been researched along with Liver Neoplasms in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (16.67) | 18.2507 |
| 2000's | 4 (11.11) | 29.6817 |
| 2010's | 16 (44.44) | 24.3611 |
| 2020's | 10 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Y; Guo, J; Huang, L; Liu, Y; Liu, Z; Wang, M; Yu, Z | 1 |
| Li, S; Li, X; Lin, K; Qu, X; Shi, Y; Wang, N; Zhang, L; Zhao, X | 1 |
| Amin, MN; El-Gayar, AM; Elleithi, YA | 1 |
| Attia, Y; El-Nabarawi, M; Mahmoud, K; Swidan, S; Teaima, M | 1 |
| Fu, R; Lou, D; Ma, X; Wu, F; Zhang, X; Zheng, D | 1 |
| Dautović, E; Halilčević, D; Hatkić, A; Husejnović, MŠ; Rustemović-Čorbić, M; Smajlović, A; Softić, A; Srabović, N | 1 |
| Cantarini, M; Fetterolf, J; Harvey, RD; Masson, E; Ramalingam, SS; So, K; Vishwanathan, K | 1 |
| Chen, K; Dai, W; Feng, J; Guo, C; Ji, J; Kong, R; Li, J; Li, S; Mao, Y; Mo, W; Wu, J; Wu, L; Xu, X; Yu, Q; Zhang, J | 1 |
| Albrecht, J; Aytaman, A; Baffy, G; Bajaj, J; Garcia-Tsao, G; Hernaez, R; Hunt, K; Ioannou, G; Johnson, K; Kanwal, F; Kaplan, DE; Lee, TH; Mehta, R; Monto, A; Pandya, P; Schaubel, D; Taddei, TH | 1 |
| Chen, L; Chen, Z; Guo, H; Han, Z; He, Y; Li, G; Liu, D; Luo, Y; Qi, L; Sun, B; Zhan, L; Zhang, N; Zhang, S; Zhu, K | 1 |
| Chen, ZN; Cui, J; Jiang, JL; Li, L; Liu, ZY; Song, F; Wu, B; Yang, XM | 1 |
| Bosch, J; Iwakiri, Y | 1 |
| Ampuero, J; Del Campo, JA; Gallego, P; Gallego-Durán, R; García-Valdecasas, M; Gil-Gómez, A; Grande, L; Muntané, J; Padillo, FJ; Pastor, H; Rojas, Á; Romero-Gómez, M | 1 |
| Bi, F; Dai, X; Fan, Z; Gong, Q; Tang, Q; Wei, G; Xia, H; Yu, H; Zhou, S | 1 |
| Beeson, CC; Beeson, GC; Christie, CF; Fang, D; Heslop, KA; Hunt, EG; Maldonado, EN; Morris, ME; Rovini, A | 1 |
| Byun, KS; Hwang, JW; Hyun, JJ; Jung, SW; Kim, JH; Koo, JS; Lee, SJ; Lee, SW; Seo, YS; Suh, SJ; Um, SH; Woo, SU; Yeon, JE; Yim, H; Yim, HJ | 1 |
| Huang, X; Ma, J; Su, Q; Xu, J; Zhao, J | 1 |
| Cheng, Z; Fu, SW; Hu, B; Ruan, LY; Wang, Y; Zheng, JN; Zheng, MH; Zhou, YY; Zhu, GQ | 1 |
| Ho, HJ; Lin, JT; Shieh, JJ; Wang, ST; Wu, CY | 1 |
| Dong, J; Fujii, S; Furumoto, T; Imagawa, S; Ishimori, N; Sato, Y; Sobel, BE; Tsutsui, H | 1 |
| Asakura, T; Fujii, S; Iwaki, S; Miyagawa, R; Nakamura, T; Okada, H; Sobel, BE | 1 |
| Henrich, D; Lehnert, M; Marzi, I; Meder, F; Relja, B; Wilhelm, K | 1 |
| Liu, W; Zhang, LF; Zhang, YH | 1 |
| Blaheta, R; Henrich, D; Lehnert, M; Marzi, I; Meder, F; Relja, B; Wang, M | 1 |
| Crespo, R; de Bravo, MG; Polo, MP | 1 |
| Bianco, AM; Crovella, S; Marcuzzi, A; Zanin, V | 1 |
| Dandri, M; Kah, J; Keller, AD; Montalbano, R; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Volz, T; Wüstenberg, A | 1 |
| Galli, C; Ghezzi, S; Priori, I; Risé, P | 1 |
| Arnaud, C; Burger, F; Mach, F; Nguyen, TH; Steffens, S; Trono, D; Veillard, NR | 1 |
| Galli, C; Marangoni, F; Petroni, A; Risé, P; Visioli, F | 1 |
| Bergstrom, JD; Bostedor, RG; Chao, YS; Geissler, WM; Rew, DJ; Wright, SD | 1 |
| Eguchi, K; Hamasaki, K; Hida, D; Kato, Y; Mazume, H; Nakao, K; Nakata, K; Tsuruta, S | 1 |
| Aldaghlas, TA; Berthold, HK; Holleran, AL; Kelleher, JK; Lindenthal, B; Sudhop, T; Von Bergmann, K | 1 |
| Hidaka, Y; Horie, M; Hotta, H; Iwasawa, Y; Kamei, T; Nagata, Y | 1 |
| Hidaka, Y; Kamei, T; Satoh, T | 1 |
| Hidaka, Y; Ishida, F; Kamei, T; Nagata, Y | 1 |
3 review(s) available for simvastatin and Liver Neoplasms
| Article | Year |
|---|---|
Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-analysis.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Neoplasms; Lovastatin; Simvastatin | 2024 |
The portal hypertension syndrome: etiology, classification, relevance, and animal models.
Topics: Adrenergic beta-Antagonists; Animals; Ascites; Carcinoma, Hepatocellular; Early Detection of Cancer; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Healthy Lifestyle; Hemorrhage; Hepatic Encephalopathy; Hepatic Veins; Humans; Hypertension, Portal; Hypolipidemic Agents; Ligation; Liver Cirrhosis; Liver Neoplasms; Models, Animal; Prognosis; Simvastatin | 2018 |
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Topics: Atorvastatin; Bayes Theorem; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Neoplasms; Lovastatin; Observational Studies as Topic; Pravastatin; Pyridines; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
2 trial(s) available for simvastatin and Liver Neoplasms
| Article | Year |
|---|---|
Impact of Disease and Treatment Response in Drug-Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non-Small Cell Lung Cancer.
Topics: Acrylamides; Administration, Oral; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Humans; Liver; Liver Function Tests; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Young Adult | 2020 |
SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation.
Topics: Esophageal and Gastric Varices; Fibrosis; Gastrointestinal Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Cirrhosis; Liver Neoplasms; Prospective Studies; Retrospective Studies; Simvastatin | 2021 |
31 other study(ies) available for simvastatin and Liver Neoplasms
| Article | Year |
|---|---|
Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Endothelial Cells; Hepatic Stellate Cells; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanoparticle Drug Delivery System; Nanoparticles; Signal Transduction; Simvastatin; Tumor Microenvironment | 2022 |
M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Carrier Proteins; Galectin 3; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Microfilament Proteins; Prognosis; Simvastatin; Tumor-Associated Macrophages | 2022 |
Simvastatin Induces Apoptosis And Suppresses Hepatocellular Carcinoma Induced In Rats.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Liver Neoplasms; Rats; Simvastatin | 2023 |
Size-optimized simvastatin-loaded TPGS modified lipid nanocapsules for targeting epithelial-to-mesenchymal transition in hepatocellular carcinoma: Role of PTEN/AKT signaling.
Topics: alpha-Tocopherol; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Lipids; Liver Neoplasms; Nanocapsules; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Simvastatin; Tissue Distribution | 2023 |
Some pleiotropic effects of statins on hepatocellular carcinoma cells: Comparative study on atorvastatin, rosuvastatin and simvastatin.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Fluorobenzenes; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Pyrimidines; Pyrroles; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2023 |
Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Glycolysis; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; PPAR gamma; Simvastatin; Sorafenib; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Xenograft Model Antitumor Assays | 2020 |
LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cholesterol; Disease-Free Survival; Down-Regulation; Female; Flavonoids; HEK293 Cells; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipogenesis; Liver; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, LDL; RNA-Seq; Simvastatin; Warburg Effect, Oncologic; Xenograft Model Antitumor Assays | 2021 |
Cytoplasmic fragment of CD147 generated by regulated intramembrane proteolysis contributes to HCC by promoting autophagy.
Topics: ADAM10 Protein; ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Amyloid Precursor Protein Secretases; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Autophagy; Basigin; Beclin-1; beta-Cyclodextrins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Leupeptins; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Proteolysis; Simvastatin | 2017 |
Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.
Topics: Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Proliferation; Cells, Cultured; Drug Therapy, Combination; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Liver Neoplasms; Metformin; Microtubule-Associated Proteins; PTEN Phosphohydrolase; Simvastatin; TOR Serine-Threonine Kinases; Tumor Protein, Translationally-Controlled 1 | 2018 |
EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction; Simvastatin; Sorafenib; Transcription Factors; YAP-Signaling Proteins | 2018 |
Statin-dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content.
Topics: Adenocarcinoma of Lung; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria, Liver; Simvastatin | 2019 |
Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclooxygenase 2 Inhibitors; Drug Synergism; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; NF-kappa B; Nitrobenzenes; Oncogene Protein v-akt; Proto-Oncogene Proteins c-bcl-2; Simvastatin; Sulfonamides | 2014 |
Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Notch1; RNA, Messenger; Simvastatin; Tumor Suppressor Protein p53 | 2015 |
Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; G1 Phase; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Resting Phase, Cell Cycle; S-Phase Kinase-Associated Proteins; Signal Transduction; Simvastatin; STAT3 Transcription Factor | 2017 |
Impact of statins on modulation by insulin of expression of plasminogen activator inhibitor type-1.
Topics: Animals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Culture Media, Conditioned; Enzyme Inhibitors; Fibrinolysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Plasminogen Activator Inhibitor 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2008 |
Increased expression of plasminogen activator inhibitor type-1 (PAI-1) in HEPG2 cells induced by insulin mediated by the 3'-untranslated region of the PAI-1 gene and its pharmacologic implications.
Topics: 3' Untranslated Regions; Binding Sites; Blotting, Western; Carcinoma, Hepatocellular; Cardiovascular Agents; Cyclic AMP; Genes, Reporter; Hep G2 Cells; Humans; Insulin; Liver Neoplasms; Oxidative Stress; Plasminogen Activator Inhibitor 1; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Up-Regulation | 2010 |
Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; G1 Phase; Humans; Liver Neoplasms; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2010 |
[Effects of simvastatin on the proliferation of HepG2 cells].
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Hep G2 Cells; Humans; Liver Neoplasms; Simvastatin | 2010 |
Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Adhesion; Cell Communication; Cell Proliferation; Cells, Cultured; Down-Regulation; Drug Evaluation, Preclinical; Endothelial Cells; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrins; Liver Neoplasms; Mevalonic Acid; rho-Associated Kinases; Simvastatin | 2011 |
Geraniol and simvastatin show a synergistic effect on a human hepatocarcinoma cell line.
Topics: Acetates; Acyclic Monoterpenes; Carcinoma, Hepatocellular; Cell Proliferation; Cholesterol; Enzyme Inhibitors; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Liver Neoplasms; Simvastatin; Terpenes | 2011 |
Clarification of the pleiotropic effects of statins on mevalonate pathway and the feedback regulation of isoprenoids requires more comprehensive investigation.
Topics: Carcinoma, Hepatocellular; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Simvastatin; Terpenes | 2012 |
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
Differential modulation by simvastatin of the metabolic pathways in the n-9, n-6 and n-3 fatty acid series, in human monocytic and hepatocytic cell lines.
Topics: Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Fatty Acids, Unsaturated; Hepatocytes; Humans; Liver Neoplasms; Methylation; Monocytes; Simvastatin; Stearic Acids | 2005 |
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver Neoplasms; Phosphorylation; Pravastatin; Protein Prenylation; Pyrroles; RNA, Messenger; Simvastatin; STAT3 Transcription Factor | 2005 |
Manipulation of the fate of long chain polyunsaturated fatty acids in cultured cells.
Topics: Arachidonic Acid; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line; Cholesterol; Enzyme Inhibitors; Ethanol; Fatty Acids, Unsaturated; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linoleic Acid; Linoleic Acids; Liver Neoplasms; Lovastatin; Mevalonic Acid; Monocytes; Neuroblastoma; Simvastatin; Tumor Cells, Cultured | 1997 |
Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Carcinoma, Hepatocellular; Cholesterol; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Liver; Liver Neoplasms; Male; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin; Transcription, Genetic; Tumor Cells, Cultured | 1998 |
Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cell Division; Chloramphenicol O-Acetyltransferase; Gene Expression Regulation; Genetic Vectors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Liver Neoplasms; Proto-Oncogene Mas; ras Proteins; Recombinant Fusion Proteins; Serum Albumin; Signal Transduction; Simvastatin; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 1999 |
Isotopomer spectral analysis of intermediates of cholesterol synthesis in human subjects and hepatic cells.
Topics: Acetates; Acetyl Coenzyme A; Carbon Isotopes; Carcinoma, Hepatocellular; Cholesterol; Duodenum; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isotope Labeling; Kinetics; Liver; Liver Neoplasms; Models, Biological; Pravastatin; Simvastatin; Tumor Cells, Cultured | 2002 |
Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in Hep G2 cells.
Topics: Acetates; Anticholesteremic Agents; Benzylamines; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Cycloheximide; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, LDL; Liver Neoplasms; Lovastatin; Mevalonic Acid; Nucleic Acid Hybridization; Oxygenases; RNA, Neoplasm; Simvastatin; Squalene Monooxygenase; Thiophenes | 1991 |
Regulation of squalene epoxidase in HepG2 cells.
Topics: Binding, Competitive; Carcinoma, Hepatocellular; Cholesterol; Detergents; Enzyme Induction; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, LDL; Liver; Liver Neoplasms; Lovastatin; Mevalonic Acid; Microsomes, Liver; Octoxynol; Oxygenases; Polyethylene Glycols; Simvastatin; Squalene Monooxygenase; Tumor Cells, Cultured | 1990 |
Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.
Topics: Anticholesteremic Agents; Carcinoma, Hepatocellular; Cholesterol; Cholesterol Esters; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Progesterone; Receptors, LDL; Simvastatin; Tumor Cells, Cultured | 1990 |